Current development of 1,2,3-triazole derived potential antimalarial scaffolds: Structure- activity relationship (SAR) and bioactive compounds

IF 6 2区 医学 Q1 CHEMISTRY, MEDICINAL
S. Maheen Abdul Rahman , Jasvinder Singh Bhatti , Suresh Thareja , Vikramdeep Monga
{"title":"Current development of 1,2,3-triazole derived potential antimalarial scaffolds: Structure- activity relationship (SAR) and bioactive compounds","authors":"S. Maheen Abdul Rahman ,&nbsp;Jasvinder Singh Bhatti ,&nbsp;Suresh Thareja ,&nbsp;Vikramdeep Monga","doi":"10.1016/j.ejmech.2023.115699","DOIUrl":null,"url":null,"abstract":"<div><p><span>Malaria is among one of the most devastating and deadliest parasitic disease<span><span> in the world claiming millions of lives every year around the globe. It is a mosquito-borne infectious disease caused by various species of the parasitic protozoan of the genus Plasmodium. The indiscriminate exploitation of the clinically used antimalarial<span><span> drugs led to the development of various drug-resistant and multidrug-resistant strains of plasmodium which severely reduces the therapeutic effectiveness of most frontline medicines. Therefore, there is urgent need to develop novel structural classes of antimalarial agents acting with unique mechanism of action(s). In this context, design and development of hybrid molecules containing pharmacophoric features of different lead molecules in a single entity represents a unique strategy for the development of next-generation antimalarial drugs. Research efforts by the scientific community over the past few years has led to the identification and development of several heterocyclic </span>small molecules as antimalarial agents with high potency, less toxicity and desired efficacy. </span></span>Triazole<span> derivatives have become indispensable units in the medicinal chemistry<span> due to their diverse spectrum of biological profiles and many triazole<span> based hybrids and conjugates have demonstrated potential </span></span></span></span></span><em>in vitro</em> and <em>in vivo</em><span><span> antimalarial activities. The manuscript compiled recent developments in the medicinal chemistry of triazole based small heterocyclic molecules as antimalarial agents and discusses various reported biologically active compounds to lay the groundwork for the rationale design and discovery of triazole based antimalarial compounds. The article emphasised on biological activities, </span>structure activity relationships<span><span>, and molecular docking studies of various triazole based hybrids with heterocycles such as quinoline, </span>artemisinins<span><span>, naphthyl, </span>naphthoquinone, etc. as potential antimalarial agents which could act on the dual stage and multi stage of the parasitic life cycle.</span></span></span></p></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"259 ","pages":"Article 115699"},"PeriodicalIF":6.0000,"publicationDate":"2023-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0223523423006669","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 3

Abstract

Malaria is among one of the most devastating and deadliest parasitic disease in the world claiming millions of lives every year around the globe. It is a mosquito-borne infectious disease caused by various species of the parasitic protozoan of the genus Plasmodium. The indiscriminate exploitation of the clinically used antimalarial drugs led to the development of various drug-resistant and multidrug-resistant strains of plasmodium which severely reduces the therapeutic effectiveness of most frontline medicines. Therefore, there is urgent need to develop novel structural classes of antimalarial agents acting with unique mechanism of action(s). In this context, design and development of hybrid molecules containing pharmacophoric features of different lead molecules in a single entity represents a unique strategy for the development of next-generation antimalarial drugs. Research efforts by the scientific community over the past few years has led to the identification and development of several heterocyclic small molecules as antimalarial agents with high potency, less toxicity and desired efficacy. Triazole derivatives have become indispensable units in the medicinal chemistry due to their diverse spectrum of biological profiles and many triazole based hybrids and conjugates have demonstrated potential in vitro and in vivo antimalarial activities. The manuscript compiled recent developments in the medicinal chemistry of triazole based small heterocyclic molecules as antimalarial agents and discusses various reported biologically active compounds to lay the groundwork for the rationale design and discovery of triazole based antimalarial compounds. The article emphasised on biological activities, structure activity relationships, and molecular docking studies of various triazole based hybrids with heterocycles such as quinoline, artemisinins, naphthyl, naphthoquinone, etc. as potential antimalarial agents which could act on the dual stage and multi stage of the parasitic life cycle.

Abstract Image

1,2,3-三唑潜在抗疟支架的最新进展:结构-活性关系(SAR)和生物活性化合物。
疟疾是世界上最具破坏性和最致命的寄生虫病之一,每年在全球夺走数百万人的生命。它是一种蚊子传播的传染病,由疟原虫属的各种寄生原生动物引起。临床上使用的抗疟药物的滥用导致了各种耐药和多重耐药疟原虫株的发展,这严重降低了大多数一线药物的治疗效果。因此,迫切需要开发具有独特作用机制的新型结构抗疟药物。在这种情况下,在单个实体中设计和开发包含不同先导分子药效学特征的杂交分子代表了开发下一代抗疟药物的独特策略。科学界在过去几年中的研究工作已经鉴定和开发了几种杂环小分子作为抗疟剂,具有高效力、低毒性和预期疗效。三唑衍生物由于其多样的生物学特性已成为药物化学中不可或缺的单元,许多基于三唑的杂化物和偶联物已在体外和体内显示出潜在的抗疟活性。该手稿汇编了三唑类小杂环分子作为抗疟剂的药物化学的最新进展,并讨论了各种已报道的生物活性化合物,为三唑类抗疟化合物的基本原理设计和发现奠定了基础。本文重点介绍了各种三唑基杂合物与喹啉、青蒿素、萘基、萘醌等杂环化合物的生物活性、构效关系和分子对接研究,这些化合物可能作用于寄生虫生命周期的双阶段和多阶段。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.70
自引率
9.00%
发文量
863
审稿时长
29 days
期刊介绍: The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信